PHG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the mixed financial performance, neutral technical indicators, and lack of strong trading signals, PHG is not a strong buy for a beginner investor seeking long-term growth. The stock should be held for now, as there are no clear positive catalysts or strong upward momentum.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 41.281, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 27.348, with key resistance at 28.345 and support at 26.351.
Philips' IntraSight Plus platform received FDA and CE clearance, which could enhance its market share in interventional cardiology. Additionally, the proposal to reappoint the CEO and introduce a new Supervisory Board member indicates stability in leadership.
Hedge funds are selling the stock significantly, with a 30126.47% increase in selling activity over the last quarter. Analysts have removed Philips from conviction lists, and recent ratings remain neutral. Financial performance shows a significant drop in net income and EPS, despite revenue growth.
In Q4 2025, revenue increased by 10.32% YoY, and gross margin improved by 15.31%. However, net income dropped by -228.70%, and EPS fell by -226.32%, indicating profitability challenges.
Analysts have a neutral stance on PHG. Goldman Sachs removed it from the European Conviction List, while Morgan Stanley and JPMorgan raised price targets slightly but maintained neutral ratings. Citi also raised the price target but kept a neutral rating.
